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Leukaemia means white blood. It is a disease of the white blood 
cells and was first described by Virchow in 1845.1 Leukaemia can 
present as an acute disease, occurring more often in the younger 
age groups, or as a chronic disease, usually in the older age group. 
Acute leukaemia is rare, but about 1 in 2 000 people will develop the 
disease.2 The two acute forms in children are acute lymphoblastic 
leukaemia (ALL) and acute myeloid leukaemia (AML). The chronic 
form is chronic myeloid leukaemia (CML).2,3 
Acute leuk aemia
Acute lymphoblastic leukaemia (ALL)
Prevalence 
ALL is the most common childhood cancer and comprises nearly 
23.5% of all cancers in the age group 0 - 14 years.3 The incidence is 
3 - 4 children per 100 000.3,4 
Pathophysiology
Leukaemia is the uncontrolled proliferation of a single immature 
haematopoietic cell with arrested or aberrant differentiation, 
resulting in clonal disease.1-3 Programmed cell death or apoptosis 
is abnormal.1 These abnormal blasts accumulate in the bone 
marrow, suppressing and replacing the normal haematopoietic 
cells, and circulate to the blood and other haematopoietic tissue.1,2 
Specific syndromes, such as Down syndrome, Fanconi’s anaemia, 
and congenital immunodeficiency syndromes, predispose to 
leukaemia.1,3 Chromosome translocations, which occur prenatally, 
are the initiating events, as shown by retrospective scrutiny of 
neonatal blood spots on Guthrie cards and ALL in identical twins.2 
This applies to all cases of infant leukaemia (fusion of the MLL 
gene) and most cases of common ALL (with TEL-AML1).2 A 
‘second hit’ after birth induces leukaemia and includes infection 
with the Epstein-Barr virus (associated with B-cell leukaemia) or 
other RNA retroviruses or ionising radiation.1,2 Early diagnosis 
is important, as delay may lead to mutations that induce drug 
resistance, with a negative impact on outcome. 
Clinical presentation
Boys are more commonly affected than girls, with a ratio of 1.2 
for 0 - 14 years and 2.2 for 15 - 19 years.4 The peak incidence is 
between 2 and 5 years of age.4 Clinical symptoms and signs reflect 
bone marrow failure, manifesting as anaemia, pallor, and abnormal 
bruising (Table I).1 Children usually present with pallor, abnormal 
bleeding (Fig.1), or easy bruising, fatigue, fever, lymphadenopathy 
and hepatosplenomegaly.4 The lympadenopathy is painless. They 
may also present with severe bone or joint pains due to lytic lesions 
(Fig. 2), which should be distinguished from normal ‘growth 
pains’ that only occur during the afternoon and do not require 
pain medication. The child usually limps or refuses to walk. These 
bone and/or joint pains occur at any time, wake the child at night 
and necessitate medication. Any pain that wakes a child during 
the night should be regarded as pathological pain. The bone pain 
may mimic rheumatoid arthritis or osteomyelitis. The duration of 
symptoms may vary from days to months.4 
The majority of children will develop common ALL, which 
characteristically has CD10 expression on the surface of the 
leukaemia blasts.4 Some children may present with a large 
mediastinal mass and a high initial white blood cell count. This 
is usually a T-cell ALL, which is also associated with a higher 
incidence of central nervous system involvement. A good prognosis 
is associated with being a girl, the age group 2 - 10 years and a 
low white blood cell count. There are geographical differences – 
common ALL is the predominant leukaemia in industrialised 
countries, while T-cell ALL is more common in developing 
countries.4 
Leuk aemia in childhood
Leukaemia is one of the more common childhood cancers.
MARIANA KRUGER, MB ChB, MMed Paed, MPhil (Applied Ethics), PhD 
Professor and Executive Head, Department of Paediatrics and Child Health,  Stellenbosch University and Tygerberg Hospital, W Cape
Mariana Kruger is a paediatric oncologist and currently executive head of the Department of Paediatrics and Child Health, Stellenbosch University and 
Tygerberg Hospital. She obtained her PhD from the Catholic University of Leuven, Belgium, with the title ‘Granulocyte-macrophage colony stimulating 
factor – more than just a growth factor’. Her interests are paediatric oncology, research ethics and children’s rights. 
Correspondence to: M Kruger (marianakruger@sun.ac.za)
320
ALL is the most common 
childhood cancer and is the 
cause of nearly 23.5% of all 
cancers in the age group  
0 - 14 years.
Table I. Clinical symptoms, signs and diagnostic 
tests for acute leukaemia 
Symptoms 
   Malaise, fatigue
   Weight loss
   Bruising
   Joint and bone pain
   Headache
Signs  
   Pallor and anaemia
    Thrombocytopenia with petechiae, ecchymosis, and/or 
epistaxis
   Fever
   Infection 
   Renal enlargement (infiltration) – rare
   Cranial neuropathy – rare
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Diagnosis
A full blood count and differential 
count will show either pancytopenia 
or anaemia, and/or thrombocytopenia 
with a high white blood cell count. The 
peripheral smear may have lymphoblasts. 
The diagnosis is made on bone marrow 
aspiration and/or bone marrow biopsy if 
there are more than 30% blasts in the bone 
marrow.1,4 Morphological classification is 
according to the French-American-British 
(FAB) classification and has 3 different 
types of ALL, based on morphology and 
cytochemistry (Table II).1 Flow cytometry 
for cell surface markers is done on bone 
marrow to determine immunophenotype, 
as these are characterised by their surface 
expression of cell surface glycoproteins, 
know as clusters of differentiation (CDs) 
(Table II).1 A panel of antibodies, directed 
at these cell surface markers, will identify 
the maturational status of the blast, 
which is used to diagnose and stratify the 
leukaemia according to risk or prognosis 
for the purpose of treatment. Cytogenetic 
studies are done to determine ploidy and 
possible translocations, which are also 
associated with prognosis, and molecular 
genetic studies are performed to determine 
genetic mutations (Table II). As mentioned 
above, the most common type is common 
ALL with CD10 surface expression and 
hyperdiploidy, which is associated with a 
good prognosis.1,4 
Other investigations include serum 
electrolytes, creatinine, calcium, and 
especially uric acid to determine 
breakdown of cells, which can cause tumour 
lysis syndrome, inducing acute renal 
failure. A lumbar puncture is performed 
to exclude central nervous system (CNS) 
involvement. Radiological studies are 
done when indicated, using radiography 
and computed tomography of the chest 
for a large mediastinal mass (associated 
with T-cell ALL) or for abdominal lymph 
nodes. If a patient is diagnosed with high-
risk leukaemia, human leucocyte typing 
is done in younger patients for potential 
future bone marrow transplantation. 
Treatment 
During the past 50 years the treatment 
of childhood ALL has been remarkable, 
because the cure rate improved from 0% 
to 80%.4 The abnormal leukaemia clone 
is eradicated with the administration 
of a combination of chemotherapeutic 
agents. However, the treatment is non-
selective and also affects the normal bone 
marrow precursors. Therefore, aggressive 
supportive care is needed, especially with 
regard to the management of infections 
(discussed in this edition of CME) 
and blood transfusions, as indicated.1,4 
Haematopoietic growth factors may be 
added to support  bone marrow function.1,4 
The goal is complete remission, defined as 
less than 5% blasts in the bone marrow. 
Treatment is divided into different phases, 
i.e. an induction phase, a consolidation 
phase, a re-induction-consolidation phase 
and maintenance with CNS prophylaxis.1,4 
The drugs administered during induction 
are vincristine, prednisone, an anthra- 
cycline and L-aspariginase.1,4,5 The 
consolidation drugs are a combination of 
cytarabine, anthracyclines, epipodophyllo-
toxins, alkylators or antimetabolites 
(methotrexate).1,4,5 Maintenance therapy 
consists of oral treatment with metho- 
trexate and 6-mercaptopurine.4 
Acute myeloid leukaemia (AML)
The incidence of AML is about 5 - 7 
children per 1 000 000 people per year 
and it comprises about 15% of childhood 
leukaemias in white children.6 The 
incidence of AML is slightly increased 
in black children.6 Children with Down 
syndrome have a 14-fold increased risk 
of developing AML, while twins have an 
increased risk in the first 6 years of life.6 
The frequency remains stable during 
childhood, with a slight increase in 
adolescence.6 The clinical presentation 
is similar to that of ALL, with fatigue, 
anaemia, a bleeding tendency and bone 
pain. Children may present with life-
threatening infections, granulocytic 
Table II. Leukaemia subtypes (adapted from DeVita et al.1)
Subtype Bone marrow morphology Immunophenotype Genotype Comments
ALL-L1  Small cells with minimal  B-lineage: CD 10; 19; 20; 22; 34; t(9;22), t(4;11), t(1;9) Most common in 
cytoplasm, no granules and rare  HLA-DR; cytoplasmic Ig hyperdiploidy children 
nucleoli, TdT+ T-lineage: CD2; 5; 7; 10; 34  
ALL-L2  Larger cells, moderate amount of  As for ALL-L1 As for ALL-L1 
cytoplasm, prominent nucleoli, TdT+ 
ALL-L3  Large round cells, deep basophilic  CD10; 19; 20;  21; 22; surface Ig t(8;14), t(2;8), t(8;22) Poor prognosis 
cytoplasm, TdT+   5% of ALL
Fig. 1. Petechiae around the nipple.
Fig. 2. Lytic bone lesions in the proximal tibia 
and distal femur.
Leukaemia is 
the uncontrolled 
proliferation of a 
single immature 
haematopoietic 
cell with arrested 
or aberrant 
differentiation, 
which results in 
clonal disease.
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granuloma or chloroma (most commonly 
orbital) and/or gum infiltration (Fig. 3).1,6 
Disseminated intravascular coagulation 
(DIC) is associated with AML-M3 or 
acute promyelocytic leukaemia (APL). 
With intensive post-remission therapy 
the event-free survival is 50%.  Failure to 
obtain the same cure rate as in ALL is due 
to the development of drug resistance and 
treatment-related mortality.6 
Diagnosis
A full blood count and peripheral smear 
are done and may present, as in ALL, with 
pancytopenia, and/or anaemia and/or 
thrombocytopenia. The white blood cell 
count may be normal, low or elevated, with 
a few patients presenting with high white 
blood cell counts of more than 100 000 
cells/µl (20%).1 The FAB morphological 
classification identifies 7 subtypes of AML 
(Table III).1,6 A bone marrow aspiration or 
biopsy is done and AML is diagnosed if 
there are more than 20% myeloblasts.7 Flow 
cytometry and cytogenetics or molecular 
genetics are done on bone marrow to 
determine the immunophenotype and 
genotype.6 
Treatment
The treatment goal is similar to that 
of ALL, i.e. to eradicate the abnormal 
leukaemic clone in the bone marrow 
using chemotherapy. The standard 
induction therapy for AML includes 
cytarabine, anthracycline, etoposide and 
dexamethasone.1,6 Favourable cytogenetics 
include t(8;21) and inv16, while children 
with Down syndrome also have a good 
prognosis.6 There are various post-
remission treatments, ranging from 
high-dose chemotherapy to autologous 
or allogeneic stem cell transplants 
(SCTs).1,6 Currently, HLA-matched family-
related SCTs are offered to patients in 
first remission if the cytogenetics are 
unfavourable and a familial donor can 
be identified. It can increase survival to 
nearly 60%.6,8 
APL (AML-M3) is a distinct entity with a 
good prognosis. If treated with standard 
induction therapy the disease has a 
high mortality rate owing to increased 
coagulopathy.1,6 Currently all-trans 
retinoic acid (ATRA) is used to induce 
Table III. Leukaemia subtypes (adapted from DeVita et al.1)
Subtype Bone marrow morphology Immunophenotype Genotype Comments
AML-M0 Type 1 blasts Cytochemistry negative CD13, 33, 34, HLA-DR NA  Poorer prognosis; 
less than 3% of child-
hood AML6
AML-M1  
Minimal Type I & II blasts  CD13, 14, 15, 33, 34,  Occasionally 20%6 
maturation Sudan black+ or peroxidase+ HLA-DR inv(3) 
 Occasional Auer rods   
AML-M2 
Maturation Types I, II 7 II blasts and monocytic cells, CD13, 15, 33, 34,  t(8;21) in 50% Translocation 
 Sudan black+, peroxidase or chloroacetate  HLA-DR  associated with a 
 esterase; Auer rods possible    favourable progno-
sis; 30% of all AML 
cases6
AML-M3 
Promyelocytic Abnormal promyelocytes; multiple CD13, 33, 15, less CD34,  t(15;17) Best prognosis;  
leukaemia  Auer rods HLA-DR negative   5 - 10% of childhood 
AML6
AML-M4 
Myelomonocytic 
leukaemia Monocytic lineage >20% and <80%; CD13, 14, 15, 33, 34,  NA Extramedullary 
 α-naphtol+ HLA-DR positive   involvement; in-
creased incidence  in 
children <2 years of 
age6
AML-M5 Large blasts >80% of monocytic lineage;  CD13, 14, 33, 34,  Abnormal Poor prognosis; 
 α-naphtol+ HLA-DR 11q23  extramedullary 
involvement; up to 
50% of childhood 
AML <2 years of age6
AML-M6 Erythroid cells >50%; non-erythroid  CD13, 33, 41, 71,  
 >30%; periodic acid-Schiff + HLA-DR,  Deletion of Often preceded  
  glycoprotein A 5 and 7 –  often   by myelodysplasia; 
poor prognosis; 
secondary AML
AML-M7 >30% blasts of megakaryocytic origin CD41, 61 Occasional  Children <3 
   inv(3); t(3;3);  years; 
   trisomy 21;  Down syndrome 
   t(9;22); t(1;22
Fig. 3. Chloroma – myeloid blast infiltration 
in the soft tissue around the eyeball.
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complete remission by the differentiation 
of the blasts into normal neutrophils, 
which is obtained in 90 - 95% of patients.1,6 
Standard AML induction therapy is then 
administered to eradicate the abnormal 
clone.1,6 The disease now has an excellent 
prognosis. 
Complications caused by chemotherapy 
include tumour lysis syndrome, DIC and 
life-threatening infections. Supportive 
care is therefore very aggressive, with 
allopurinol and hyperhydration for 
tumour lysis syndrome, plasma and low-
dose heparin for DIC, and combination 
broad-spectrum intravenous antibiotics6 
(see article on febrile neutropenia in this 
edition of CME).
Chronic leuk aemia
Chronic myeloid leukaemia 
(CML)
Prevalence
Chronic leukaemia is very rare in 
childhood and comprises only 5% of 
childhood leukaemias.9,10 The majority of 
children diagnosed with CML are older 
than 6 years. 
Pathophysiology
CML has the phenotype of more mature 
cells.9 It is a clonal disease, involving 
a pluripotent stem cell. On clinical 
presentation, it is in an indolent chronic 
or a stable phase with excessive numbers 
of myeloid cells in both the peripheral 
blood and bone marrow.9,10 Philadelphia 
chromosome or t(9;22) is characteristic 
of CML as the cytogenetic marker, 
which is found in myeloid, erythroid and 
megakaryocytic lineages. This marker is 
also found in B cells and a small proportion 
of T cells, confirming the clonality of the 
disease originating from a pluripotent 
haematopoietic stem cell. About 5 - 10% 
of patients with CML may be Philadelphia 
chromosome negative.9 The translocation 
between chromosomes 9 and 22 leads to 
the development of the BCR-ABL fusion 
protein with tyrosine kinase activity, which 
activates several signalling pathways that 
decrease apoptosis, enhance proliferation 
of haematopoietic stem cells, and increase 
the number of myeloid cells with early 
release from the bone marrow into the 
peripheral blood.9,10 
Clinical presentation 
Patients with CML usually present in the 
chronic or stable phase with an elevated 
white blood cell count and few or no 
symptoms.9,10 Symptoms include night 
sweats, fever, bone pain, weakness and 
discomfort due to an enlarged spleen.9 
After 4 - 6 years the disease progresses 
into an accelerated phase or a blastic 
phase, when the blasts can no longer 
terminally differentiate.10 These children 
will present with fatigue, anaemia, 
weight loss, abdominal distension and 
splenomegaly, where the size correlates 
with the leukocytosis. Patients rarely 
present with hyperviscosity resulting in 
stroke or priapism.10 
Diagnosis
The white blood cell count is high 
(>50×109/l), while the white blood cell 
function is normal during the chronic 
phase.10 Basophilia, eosinophilia and 
thrombocytosis are often present.10 During 
the blast crisis the majority of blasts are 
myeloblasts, but one-third may have a 
lymphoid morphology, usually early B-cell 
markers.9 
Treatment
Treatment options for CML include various 
chemotherapy drugs and allogeneic 
SCTs.10 The drugs used in CML include 
busulfan, hydroxyurea and interferon alfa. 
Imatinib mesylate (Gleevec), an oral drug, 
is currently the drug of choice.9 Imatinib is 
a small 2-phenylaminopyrimidine, which 
inhibits the BCR-ABL protein binding 
of ATP and suppresses the malignant 
clone.9,11 The majority of patients 
(96%) achieve complete haematological 
remission, with a 99% 24-month survival if 
a major cytogenetic response is obtained.11 
The only permanent curative therapy is 
allogeneic SCT, resulting in a 10-year 
disease-free survival rate of  50 - 60%. 
This is obtained if the SCT is done in the 
chronic phase of the disease.10 There is 
currently a debate around which of the 
two therapies, i.e. imatinib or SCT, is the 
preferred treatment, as children have a 
survival rate of 65 - 75% with SCT.9,12
Brief guidelines for 
referral to a paediatric 
oncologist
•    Refer a child who presents with the 
following:
•    abnormal bleeding tendency
•    lymphadenopathy with/without hepa-
tosplenomegaly
•    weight loss in the presence of abnormal 
haematological findings
•    bone pain, arthralgia or arthritis in the 
presence of abnormal haematological 
findings
•    an unexplained high white blood cell 
count, pancytopenia, bicytopenia or 
monocytopenia of unknown origin.
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